Loading organizations...
Based in Boston, Massachusetts, Droplette develops a physics-powered skincare device that transforms proprietary serum capsules into a micro-mist for deep dermal penetration. The direct-to-consumer hardware and consumables business operates with 109 employees and generates approximately $33 million in annual revenue after securing $24.2 million in total funding. Utilizing patented fluid physics technology originally researched for treating rare skin disorders, the system delivers pharmaceutical-grade ingredients clinically shown to increase hydration by 94 percent and reduce fine lines by 87 percent. The enterprise has secured research grants and formed strategic partnerships with prominent organizations including NASA, the NIH, and the US Army for advanced dermatological applications. Droplette recently launched its optimized second-generation device and has been featured in major consumer publications such as Vogue and Allure. The biotechnology company was founded by MIT-trained scientists Madhavi Gavini and Rathi Srinivas.
Droplette has raised $21.0M across 1 funding round.
Droplette has raised $21.0M in total across 1 funding round.
Droplette is a beauty tech startup that builds an at-home skincare system featuring a patented device and proprietary serum capsules, delivering pharmaceutical-grade ingredients deep into the skin via a high-velocity mist without needles or pain[1][2][4][5]. It serves skincare consumers seeking advanced anti-aging and hydration solutions, solving the key problem of topical products' inability to penetrate the skin barrier effectively—achieving 20X better delivery and clinically proven results like 94% improved hydration and 87% reduction in fine lines[1][4][5]. The company has shown growth momentum through a $15.4 million Series B in 2021 to expand manufacturing and markets, NASA/NIH backing, and strong consumer reviews[2][7].
Droplette was founded in 2017 by MIT-trained engineers Madhavi Gavini (CEO) and Rathi Srinivas, who pivoted medical device technology—originally developed for treating rare skin diseases and backed by NASA and NIH—into consumer skincare[2][3][7]. The core innovation emerged from research on transdermal delivery of large biomolecules like nucleic acids using a portable, contact-free system combining a piezoelectric transducer and pneumatic diaphragm pump, tested in vitro, in vivo, and human studies[3]. Early traction included peer-reviewed publications, US patents (e.g., US 9,700,686 B2), partnerships like the US Army for dermatological applications, and a shift to direct-to-consumer sales of the device and serums[2][3][7].
Droplette rides the beauty tech wave merging consumer skincare with medtech innovations like transdermal drug delivery, capitalizing on demand for needle-free, efficacious at-home alternatives to in-office treatments amid rising clean beauty and personalization trends[2][3][7]. Timing aligns with post-pandemic self-care booms and advancements in piezo-pneumatic tech, enabling scalable consumer access to pharma-grade results previously limited to clinics or labs[1][2][8]. Market forces like aging populations, e-commerce growth, and investor interest (e.g., Series B from Victress Capital) favor it, while its medical roots position it to influence ecosystems from cosmetics to gene therapy and inflammatory skin treatments[2][3].
Droplette is poised to expand its skincare lineup, automate capsule production, and enter new markets, potentially evolving into therapeutics with its versatile platform for drug/nucleic acid delivery[2][3]. Trends like AI-personalized beauty, sustainable biotech, and regulatory nods for at-home med devices will shape its path, amplifying influence in consumer health. As the pioneer in painless deep-skin infusion, it redefines "skincare on a deeper level," turning medical breakthroughs into daily rituals for transformative results[1][4].
Droplette has raised $21.0M across 1 funding round. Most recently, it raised $21.0M Series B in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $21M Series B | — | Victress Capital | Announced |
Droplette has raised $21.0M in total across 1 funding round.
Droplette's investors include Victress Capital.